Progress of minimal residual disease detection in precision medicine of lymphatic malignancies / 白血病·淋巴瘤

ABSTRACT

With the great progress of precise medicine for lymphatic malignancies, minimal residual diseases (MRD) play an increasingly important role in their evaluation of treatment response, prognosis judgement, treatment decision guidance, and recurrence prediction. At present, nearly a thousand articles on hematological malignancies related to MRD detection are published annually. At the 65th American Society of Hematology annual meeting in 2023, nearly 500 articles on the application of MRD detection in the diagnosis and treatment of lymphatic malignancies cover a wide and rich range of content. This paper reviews the oral reports of MRD detection in acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma and lymphoma.